Menorah focuses on inherited forms of sensorineural deafness, having licensed IP from UNSW Sydney's molecular medicine group. Their lead candidate is in preclinical validation with a potential Phase I readout in 2026. The Sydney-based biotech has raised commitments from both local and international venture partners.